UPDATE: Philly jury hits J & J ’ s Ethicon with $41m judgment in pelvic mesh case

Updated to include a response from Ethicon. Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon has been hit with a $41 million verdict in a pelvic mesh product liability suit in Philadelphia, according to a report from the Mesh News Desk. A jury in Philadelphia found that Ethicon’s Gynemesh, Prolift and TVT-O meshes were defective, and that the company was negligent in manufacturing the devices, according to the report. The plaintiff, Suzanne Emmett, was implanted with a Prolift pelvic mesh to treat pelvic organ prolapse, a TVT-O mesh as a treatment for incontinence and a Gynemesh implant, according to the Mesh News Desk report. The verdict includes $25 million in punitive damages, $15 million in compensation and $1 million to Emmett’s husband, according to the report. A spokesperson for Ethicon said in an email to MassDevice.com that it intends to appeal the decision and that it stands by its pelvic mesh products. The company said that it believes that the decision contradicts evidence that its pelvic mesh devices were properly designed, and that it appropriately informed surgeons of known risks. “Pelvic organ prolapse and stress urinary incontinence are serious and debilitating conditions with limited treatment options. Scientists from around the world who have conducted and reviewed independent research on pelvic mesh agree it is an important treatment option for some women. All surgeries to treat these conditions have risks. While we empathize with those who...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Legal News Women's Health Ethicon johnsonandjohnson Source Type: news